NCT02713477View on ClinicalTrials.gov

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Insulin glargine HOE901

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Placebo

"Pharmaceutical form: solution~Route of administration: subcutaneous"

Trial Locations (1)

Unknown

Investigational Site Number 392001, Fukuoka

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY